抄録
Concerning dose of urokinase, much amount of it has been administered in U.S.A. and European countries (8, 9, 10, 11). The authors investigated on the effects of urokinase on coagulation, fibrinolysis and platelets by in vitro and in vivo studies.
(1) Urokinase showed fibrinolysis rather than fibrinogenolysis, and made PTT shorter in its clotting time from activation of Factor XII, and damaged platelet function in in vitro and in vivo studies. The rabbits who were infused 6,000 to 60,000 CTA units of urokinase showed many microthrombi in lungs and kidneys.
(2) Heparin showed the promoting effect on fibrinolytic activity of urokinase in in vitro studies, and when urokinase was infused into the rabbits with heparin no microthrombi were observed in the lungs and kidneys.
(3) In clinical case, when urokinase was administered alone, PTT was shortened, platelet retention rate was decreased, but elevated fibrinolysis was observed for 6 to 8 hours at 12,000 units of it. For prevention of the coagulation system from hyper-coagulable state, 12,000 CTA units of urokinase was administered with 5,000 units of heparin three times per day for five days, and then anti-coagulant therapy using coumarine was applied continually. If the clinical signs were not improved, urokinase was again administered with this anti-coagulant therapy.
